This Biotech Isn’t Dead Yet. It’s Just Getting Its Second Wind

Let me let you in on a little Wall Street secret: Merck & Co. (MRK) is having what my grandmother used to call “a spell,” and it’s not the kind that ends with Mai Tais on a cruise ship.

Down 18% year-to-date, Merck’s been standing quietly in the corner like the designated driver at an afterparty: sober, responsible, and completely ignored while everyone else chases the latest sugar high.

But if you’ve been around the block a few times, you know that markets eventually come home to fundamentals. And Merck? It’s sitting on some pretty solid ones.

First, let’s talk about Keytruda. This is Merck’s golden goose, crown jewel, and cash printer rolled into one.

It’s hauling in nearly $30 billion a year – close to half the company’s revenue. But like all good things in pharma, it’s got a ticking clock.

The patent falls off a cliff in 2028, and that’s got analysts sweating like it’s earnings season during a rate hike.

The market, in its usual overreacting wisdom, assumes Merck’s executive team is just going to wait out the clock, knitting scarves and sipping herbal tea until the end.

But the reality? They’re spending like they actually plan to stick around.

A full 28% of revenue goes straight into R&D. Definitely no penny pinching here.

For comparison, Johnson & Johnson (JNJ) clocks in at 19.4%. And Pfizer (PFE)? A modest 17%. Merck is playing chess while the others are refreshing their résumés.

Then there’s the China wrinkle.

Gardasil, Merck’s blockbuster HPV vaccine, was doing brisk business overseas until Beijing suddenly pulled the plug in February.

Official story? “Weak demand.” Anyone who’s done business in China knows that phrase is about as transparent as a foggy window.

Let’s just say there are likely more levers being pulled behind the curtain.

Add to that the looming pressure of the Inflation Reduction Act, and you’ve got a cocktail of investor anxiety that’s priced Merck like it’s already halfway to hospice.

But here’s the thing: by my math (and I’ve been modeling these things since traders used fax machines) Merck is trading roughly 23% below intrinsic value.

That’s with a conservative beta bump and enough doomsday scenarios baked in to make a prepper proud.

The fundamentals remain impressive.

Operating margins at 31.5%? That’s not just healthy, it’s downright athletic. Return on assets sits at 14.6%, while most of the sector struggles to crack 4%.

The balance sheet is firm, with a debt-to-equity ratio of 0.80 and interest coverage that won’t keep anyone up at night.

These numbers don’t tell the story of a troubled company. Instead, these tell me about a misunderstood heavyweight taking a breather between rounds.

On top of these, the pipeline is no slouch.

MK-0616, a cholesterol pill with blockbuster potential, is deep in Phase 3 and expected to land right as Keytruda starts to fade.

Meanwhile, Winrevair, a newly approved cardiovascular drug, is already on pace to top $1.5 billion this year. That’s not luck. That’s planning.

Their $20 billion capital spending spree through 2028 isn’t about vanity projects either. It’s manufacturing capacity, digital infrastructure. Not really exciting updates, but most definitely smart moves.

So, what’s the play? Merck isn’t a moonshot. It’s not the stock you tell your buddies about over golf because it’s going to triple in a week.

But it is a stable buy for anyone who’s seen enough cycles to know that quality tends to come back in style especially when the market is pricing in Armageddon.

Besides, sometimes the best opportunities are hiding in plain sight: sturdy, unloved, and momentarily out of favor.

Merck may not be the prom queen anymore, but give it a few quarters… and you might just find it leading the dance.